Search Result for : Pharma Sector

The Dollar Business Bureau In a bid to facilitate exports and make easier to do business, the Government on Wednesday eased the guidelines for drugs, medical devices and cosmetics exporters. Now the pharmaceutical companies will no longer have to get ‘no-objection’ certificate (NOC) from regulatory authority to export drugs and medical devices. “The pharmaceutical exporters can continue exporting without having to obtain no-objection certificates (NOC) from the regulatory authorities,” said the Central Drugs Standard Control Organisation (CDSCO) in a notice. Earlier, this facility was only available for exports to Australia, US, Japan, Canada, and European Union. Now CDSCO has extended the rule for exports to all other countries. “In partial modification of notice of even number dated December 11, 2015, removing the requirement of NOC for ...

Ahmad Shariq Khan Indonesia’s Ambassador to India Arto Suryodipuro has said that India’s maritime industry has enormous potential and the country’s ambitious port-led economic development plan is very much in line with Indonesia's efforts to improve maritime infrastructure and connectivity in the region “India’s maritime industry has enormous potential,” the Ambassador said while speaking at the 2nd edition of the Indonesia Exposé 2017 organized by the Embassy of Republic of Indonesia in New Delhi. “India has experience in connectivity packaged in the integration of industrial zones, ports and inland waterways, where almost all transportation routes - land, river and sea - are connected to each other,” he said. “India now has advanced port management, transshipment and logistics capability,” Suryodipuro said, adding that India’s ambitious ...

The Dollar Business Bureau A leading Indian pharmaceuticals company Aurobindo Pharma has said that it would widen its product portfolio in the American market while planning to enter new markets in the Europe, a part of the company’s growth strategy in the coming 3-4 years. In the US market, Aurobindo Pharma plans to widen its portfolio through faster growth in OTC, injectable and higher complexity products, the company said in a presentation to investors. However, in European market, the company plans to enhance its presence in new geographies like Czech Republic and Poland, in addition to strengthening its position in the existing markets of Germany, France, Spain, Netherlands and the UK. Aurobindo Pharma is the 6th largest generic company by volume in the US, ...

Sneha Gilada Bio Asia 2017, a global healthcare exhibition and conference, started on February 6, 2017, here in  Hyderabad. The three day event was inaugurated by the Telangana Governor ESL Narsimhan. Early into the second day of Bio Asia, packed halls witnessed eminent speakers from the pharma industry sharing their future vision for the global healthcare sector. The 14th edition of Bio Asia, as the theme suggests, was a platform for delegates, coming from more than 50 countries, to collaborate and leverage India's potential in achieving quality healthcare for billions all over the world. Dr. Paul Stoffels, Worldwide Chairman of Pharma, Johnson & Johnson(J&J) The must-attend event for any healthcare enthusiast saw participation from more than 800 corporates, and over 100 high-profile speakers. The morning session on February 7 had a special address from the likes of  Dr. Paul Stoffels, Worldwide Chairman ...

The Dollar Business Bureau  The Cabinet on Wednesday approved the sale of surplus land of the country’s first pharma company Bengal Chemicals and Pharmaceuticals Ltd. as well as Hindustan Antibiotics Ltd. The Cabinet headed by Prime Minister Narendra Modi also approved closure of Indian Drugs and Pharmaceuticals Ltd. (IDPL) and Rajasthan Drugs and Pharmaceuticals Ltd. (RDPL).  This is second such strategic sale approved in over 12 years. In September, the Prime Minister-chaired Cabinet had cleared the strategic sale of Bharat Pumps and Compressors Ltd. In 2003-04, the then Prime Minister Atal Bihari Vajpayee had approved the first strategic privatisation of Jessop and Co. Earlier, NITI Aayog had identified BCPL and HAL as the two public sector units for sale of government's majority stake to private companies ...

The Dollar Business Bureau Suven Life Sciences (Suven) on Tuesday announced it has received approvals of one product patent each from India and South Africa.  “One product patent from India and one product patent from South Africa corresponding to the New Chemical Entities (NCEs) for treatment of disorders associated with neuro-degenerative diseases," the company said in an announcement.   These two patents are valid through 2028 and 2032 respectively. The granted patents include the class of 5-HT6 compounds and H3 inverse agonist compounds. There are being developed as therapeutic agents and will be used for the treatment of cognitive impairment related to neurodegenerative disorders such as Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, major depressive disorder (MDD), Parkinson and Schizophrenia. With the grants of ...

The Dollar Business Bureau Sun Pharmaceutical on Monday announced that it is planning to sell its two oral solid dosage manufacturing plants to Frontida BioPharm Inc in the United States. “Frontida has agreed to continue manufacturing certain products for Sun Pharma at these facilities on a contract basis for a predetermined period. It has also agreed to offer employment to all production, quality and administrative personnel at the sites,” Gurgaon-based pharma company said in a statement. “The effect of this deal on Sun Pharmaceutical’s overall financials and activities is not material,” it added. The drug major also stated it was aware about ensuring the continued supply of quality products to patients during the divestment process. This is the second divestment ...

The Dollar Business Bureau Rating agency ICRA on Thursday said that the Indian pharmaceutical industry will witness moderation in growth due to slow down of business in the US with a decline in the volume of large size drugs going off patent, increasing competition and adoption of generics reaching a saturation level. Over the last 10 years, the Indian pharmaceutical companies have witnessed a strong growth driven largely by the US market. "However, the growth from the US market has been down to 15 percent in financial year 2015-16 and looking forward the momentum for growth is possibly to face more pressure," ICRA (Investment Information and Credit Rating Agency of India) said in a statement. The Indian drug companies will have an impact on ...